HAVCR2 and ovarian cancer: In contrast to our results, Guo et al. studied the treatment of anti-TIM3 in a similar intraperitoneal mouse model for ovarian cancer (ID8), where they observed a significant prolongation of survival when injecting anti-TIM3 in monotherapy on day three after tumor inoculation.